RxSight RXST 深 滬
等待開盤 08-10 09:30:00 美东时间
6.26
+0.180
+2.96%
華盛通- 最 高6.295
- 今 開6.03
- 成交量 62.77万股
- 最 低 5.94
- 昨 收 6.08
- 總市值 2.59亿
- 52周最高 13.22
- 市盈率 靜 --
- 換手率 1.52%
- 52周最低 4.48
- 委 比 12.54%
- 總股本 4139.66万
- 歷史最高 66.54
- 量 比 0.67
- 振 幅 5.84%
- 歷史最低 4.48
- 每 手 1
- 風險率 2.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
UBS Maintains Neutral on RxSight, Raises Price Target to $6.3
UBS analyst Patrick Wood maintains RxSight (NASDAQ:RXST) with a Neutral and raises the price target from $5.5 to $6.3.
08-07 03:39
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RxSight, Inc. granted stock options and restricted stock units (RSUs) to its new CEO, Aziz Mottiwala, totaling 571,286 shares and 2,312,138 shares, respectively. The stock options have an exercise price of $5.19 per share, vesting 25% after one year and monthly thereafter. The RSUs vest 20% after one year, 20% after two years, and 60% after three years. The awards were granted under the 2026 Inducement Equity Incentive Plan to induce Mr. Mottiwal...
07-26 20:00
RxSight appoints new CEO
RxSight (RXST) appointed Aziz Mottiwala as president and chief executive officer, effective July 20, 2026. Mottiwala succeeds Ron Kurtz, M.D., who will remain with the company as chief medical officer...
07-16 04:18
RxSight Appoints Aziz Mottiwala President, CEO, Effective July 20, Succeeding Ron Kurtz
RxSight, Inc. (NASDAQ:RXST) today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and Chief Executive Officer, succeeding Ron Kurtz, M.D., who will continue to serve as Chief Medical Officer.
07-16 04:16
律所对RxSight发起调查，涉及2025年业绩披露引发股价暴跌
Glancy Prongay Wolke & Rotter LLP宣布对眼科医疗设备公司RxSight启动调查，关注董事会是否违反了对股东的信托义务...
07-11 03:41
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
Needham Reiterates Buy on RxSight, Maintains $11 Price Target
Needham analyst David Saxon reiterates RxSight (NASDAQ:RXST) with a Buy and maintains $11 price target.
07-07 18:06
RxSight Sees Q2 Sales $32.000M-$34.000M vs $32.077M Est
RxSight (NASDAQ:RXST) sees Q2 sales of $32.000 million-$34.000 million vs $32.077 million analyst estimate.
07-07 04:50
